DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

DEK is a transcription factor involved in stabilization of heterochromatin and cruciform structures. It plays an important role in development and progression of different types of cancer. This study aims to analyze the role of DEK in metastatic colorectal cancer.

Detalhes bibliográficos
Autores: Martinez-Useros, Javier, Rodriguez-Remirez, Maria, Borrero-Palacios, Aurea, Moreno, Irene, Cebrian, Arancha, Gomez del Pulgar, Teresa, del Puerto-Nevado, Laura, Vega-Bravo, Ricardo, Puime-Otin, Alberto, Perez, Nuria, Zazo, Sandra, Senin, Clara, Fernandez-Aceñero, Maria J, Soengas, MS, Rojo, Federico, Garcia-Foncillas, Jesus
Formato: artículo
Fecha de publicación:2014
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/25424
Acesso em linha:https://hdl.handle.net/20.500.12105/25424
Access Level:acceso abierto
Palavra-chave:DEK
Irinotecan
Aggressive phenotype
Metastatic colorectal cancer
KRAS
id ES_f52f0fa08231aaafc56f1666e84a5da2
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/25424
network_acronym_str ES
network_name_str España
repository_id_str
spelling DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.Martinez-Useros, JavierRodriguez-Remirez, MariaBorrero-Palacios, AureaMoreno, IreneCebrian, AranchaGomez del Pulgar, Teresadel Puerto-Nevado, LauraVega-Bravo, RicardoPuime-Otin, AlbertoPerez, NuriaZazo, SandraSenin, ClaraFernandez-Aceñero, Maria JSoengas, MSRojo, FedericoGarcia-Foncillas, JesusDEKIrinotecanAggressive phenotypeMetastatic colorectal cancerKRASDEK is a transcription factor involved in stabilization of heterochromatin and cruciform structures. It plays an important role in development and progression of different types of cancer. This study aims to analyze the role of DEK in metastatic colorectal cancer.BioMed Central (BMC)Instituto de Salud Carlos III20242024-11-0420142014-12-1620142014-12-16research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/25424reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)InglésengMinisterio de Economía y Competitividad http://dx.doi.org/10.13039/501100003329 Not available PI12%2F01552 Identificación de mecanismos de resistencia a nuevos anticuerpos anti-HER2 en cáncer de mamaMinisterio de Ciencia e Innovación http://dx.doi.org/10.13039/501100004837 Not available CSD2009-00080 An integrated approach to post-transcriptional regulation of gene expression and its role in human diseaseopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/254242026-06-12T12:43:37Z
dc.title.none.fl_str_mv DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
title DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
spellingShingle DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros, Javier
DEK
Irinotecan
Aggressive phenotype
Metastatic colorectal cancer
KRAS
title_short DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
title_full DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
title_fullStr DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
title_full_unstemmed DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
title_sort DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
dc.creator.none.fl_str_mv Martinez-Useros, Javier
Rodriguez-Remirez, Maria
Borrero-Palacios, Aurea
Moreno, Irene
Cebrian, Arancha
Gomez del Pulgar, Teresa
del Puerto-Nevado, Laura
Vega-Bravo, Ricardo
Puime-Otin, Alberto
Perez, Nuria
Zazo, Sandra
Senin, Clara
Fernandez-Aceñero, Maria J
Soengas, MS
Rojo, Federico
Garcia-Foncillas, Jesus
author Martinez-Useros, Javier
author_facet Martinez-Useros, Javier
Rodriguez-Remirez, Maria
Borrero-Palacios, Aurea
Moreno, Irene
Cebrian, Arancha
Gomez del Pulgar, Teresa
del Puerto-Nevado, Laura
Vega-Bravo, Ricardo
Puime-Otin, Alberto
Perez, Nuria
Zazo, Sandra
Senin, Clara
Fernandez-Aceñero, Maria J
Soengas, MS
Rojo, Federico
Garcia-Foncillas, Jesus
author_role author
author2 Rodriguez-Remirez, Maria
Borrero-Palacios, Aurea
Moreno, Irene
Cebrian, Arancha
Gomez del Pulgar, Teresa
del Puerto-Nevado, Laura
Vega-Bravo, Ricardo
Puime-Otin, Alberto
Perez, Nuria
Zazo, Sandra
Senin, Clara
Fernandez-Aceñero, Maria J
Soengas, MS
Rojo, Federico
Garcia-Foncillas, Jesus
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
dc.subject.none.fl_str_mv DEK
Irinotecan
Aggressive phenotype
Metastatic colorectal cancer
KRAS
topic DEK
Irinotecan
Aggressive phenotype
Metastatic colorectal cancer
KRAS
description DEK is a transcription factor involved in stabilization of heterochromatin and cruciform structures. It plays an important role in development and progression of different types of cancer. This study aims to analyze the role of DEK in metastatic colorectal cancer.
publishDate 2014
dc.date.none.fl_str_mv 2014
2014-12-16
2014
2014-12-16
2024
2024-11-04
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/25424
url https://hdl.handle.net/20.500.12105/25424
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Ministerio de Economía y Competitividad http://dx.doi.org/10.13039/501100003329 Not available PI12%2F01552 Identificación de mecanismos de resistencia a nuevos anticuerpos anti-HER2 en cáncer de mama
Ministerio de Ciencia e Innovación http://dx.doi.org/10.13039/501100004837 Not available CSD2009-00080 An integrated approach to post-transcriptional regulation of gene expression and its role in human disease
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central (BMC)
publisher.none.fl_str_mv BioMed Central (BMC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424566543056896
score 15,812429

Registos relacionados